115 related articles for article (PubMed ID: 20238466)
1. Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Lefebvre MC; Hunsche E
Appl Health Econ Health Policy; 2010; 8(1):69-71; author reply 71-3. PubMed ID: 20238466
[No Abstract] [Full Text] [Related]
2. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Dranitsaris G; Mehta S
Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
[TBL] [Abstract][Full Text] [Related]
3. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Montani D; Humbert M
Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
[No Abstract] [Full Text] [Related]
4. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological treatment of pulmonary hypertension at a turning point].
Watanabe H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):165-72. PubMed ID: 24717603
[No Abstract] [Full Text] [Related]
6. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
[TBL] [Abstract][Full Text] [Related]
7. Summaries for patients. A combination treatment for pulmonary hypertension.
Ann Intern Med; 2008 Oct; 149(8):I-38. PubMed ID: 18936497
[No Abstract] [Full Text] [Related]
8. Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.
El Midany AA; Mostafa EA; Azab S; Hassan GA
Interact Cardiovasc Thorac Surg; 2013 Dec; 17(6):963-8. PubMed ID: 23985411
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.
Vachiery JL; Huez S; Gillies H; Layton G; Hayashi N; Gao X; Naeije R
Br J Clin Pharmacol; 2011 Feb; 71(2):289-92. PubMed ID: 21219411
[TBL] [Abstract][Full Text] [Related]
10. Macitentan (Opsumit) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
[No Abstract] [Full Text] [Related]
11. [Treatment of idiopathic pulmonary arterial hypertension].
Andreassen AK; Gude E; Solberg OG; Ueland T
Tidsskr Nor Laegeforen; 2011 Jul; 131(13-14):1285-8. PubMed ID: 21725387
[TBL] [Abstract][Full Text] [Related]
12. "Out of the blue"-safety and efficacy of pulmonary hypertension treatment in childhood*.
Kraemer U; Wildschuth E; Tibboel D
Pediatr Crit Care Med; 2014 May; 15(4):377-8. PubMed ID: 24801422
[No Abstract] [Full Text] [Related]
13. Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources.
Vida VL; Gaitan G; Quezada E; Barnoya J; Castañeda AR
Cardiol Young; 2007 Feb; 17(1):72-7. PubMed ID: 17184573
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension.
Behzadnia N; Najafizadeh K; Sharif-Kashani B; Dameshghi DO; Shahabi P
Heart Vessels; 2010 Jul; 25(4):313-8. PubMed ID: 20676840
[TBL] [Abstract][Full Text] [Related]
15. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease.
Lu XL; Xiong CM; Shan GL; Zhu XY; Wu BX; Wu GH; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Zhang DZ; Li WM; Zhang C; Tian HY; Guo YJ; Guo T; Liu HM; Zhang WJ; Gu H; Huang SA; Chen JY; Wu WF; Huang K; Li JJ; He JG
Cardiovasc Ther; 2010 Dec; 28(6):350-5. PubMed ID: 20637015
[TBL] [Abstract][Full Text] [Related]
16. Hoarseness revealing Ortner's syndrome.
Verbeke X; Vliebergh J; Sauer M; Leys M
Acta Clin Belg; 2015 Jun; 70(3):230. PubMed ID: 26103539
[TBL] [Abstract][Full Text] [Related]
17. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension.
Lee WT; Kirkham N; Johnson MK; Lordan JL; Fisher AJ; Peacock AJ
Eur Respir J; 2011 Feb; 37(2):472-4. PubMed ID: 21282815
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
[TBL] [Abstract][Full Text] [Related]
20. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
Safdar Z
Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
